← Leaderboards
Hemn Mohammadpour
Roswell Park Cancer Institute Corp
$1,062,412
Attributed
$1,062,412
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $366.9K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,062,412 · 3
By mechanism
R00$747,000 · 1
K99$235,728 · 1
F32$79,684 · 1
Top collaborators
No co-investigators on record.
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Elizabeth Repasky$12,725,917
- Xuefang Cao$8,586,764
- Cameron Riker Macdonald$169,092
- Caitlin M James$77,689
- Jee Eun Choi$120,842
Others in their field
Other Emerging Leaders on “Play”
- Chanza Baytop · Westat, Inc.$271,217,917
- John E West · University Of Texas At Austin$97,000,000
- Scott Topper · Broad Institute, Inc.$40,042,399
- Priyamvada Acharya · Duke University$22,519,941
- Bronwen Shaw · Medical College Of Wisconsin$19,560,999
- Oliver Brand · Emory University$18,288,469
Research focus
PlayT-LymphocyteMentorsPathway InteractionsSignal TransductionTissuesImmunotherapyMalignant NeoplasmsCellsMyeloid CellsResearch PersonnelResponseAffectSkillsBiologyImmuneBone MarrowMacrophageCd4 Positive T LymphocytesCancer TherapyCell PhysiologyMouse ModelRecombinantsTraining
Grant awards (7)
Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) Responses$249,000
R00 · FY2024 · HL · contact PI
Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) Responses$249,000
R00 · FY2023 · HL · contact PI
Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GVT) Responses$249,000
R00 · FY2022 · HL · contact PI
Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GvT) Responses$117,864
K99 · FY2022 · HL · contact PI
Implication of Galectin-3 to regulate Graft vs. Host Disease (GvHD) and Graft vs. Tumor (GvT) Responses$117,864
K99 · FY2021 · HL · contact PI
Overcoming stress driven suppression of the anti-tumor immune response in cancer - understanding the MDSC piece of the puzzle$12,238
F32 · FY2021 · CA · contact PI
Overcoming stress driven suppression of the anti-tumor immune response in cancer - understanding the MDSC piece of the puzzle$67,446
F32 · FY2020 · CA · contact PI